Santhera Pharmaceuticals Narrows First-Half Loss as AGAMREE Crosses Milestone Threshold

Santhera's H1 2026 revenue more than doubled to 48.3M CHF, triggering a 20M USD AGAMREE milestone payment; full-year guidance held at 80-90M CHF.

Santhera Pharmaceuticals posted sharply higher revenue for the first six months of 2026 while simultaneously triggering a contractual payment tied to its flagship drug, AGAMREE. The company disclosed the figures yesterday, with management walking investors through the interim results during an afternoon conference call.

Group revenue for the period reached 48.3 million CHF, more than doubling from 24.0 million CHF a year earlier — a jump of 101 percent. That top-line momentum fed directly into the operating result, cutting the operating loss to 6.6 million CHF from 35.4 million CHF in the prior-year period.

AGAMREE clears 175 million USD mark

The engine behind the improvement remains AGAMREE. Measured on a trailing four-quarter basis, worldwide AGAMREE revenue including partner contributions surpassed 175 million USD during the second quarter of 2026. Crossing that level activated a contractual milestone payment of 20 million USD owed to ReveraGen — equivalent to 16.3 million CHF that Santhera must now fund.

Even with that obligation on the books, the bottom line improved markedly. The net loss for the reporting period came in at 21.526 million CHF, down from 38.832 million CHF in the comparable prior-year stretch.

Pure product sales climbed 48 percent to 17.2 million CHF across the first half, reinforcing the commercial trajectory that has become central to Santhera's financial story.

Full-year targets held steady

Management reaffirmed its guidance for the full year 2026. Group revenue is projected to land between 80 million CHF and 90 million CHF. On the product side, the company anticipates growth exceeding 50 percent versus the previous year, banking on continued rollout of its lead medicine to carry it there.

Whether that demand holds through the second half will determine if Santhera can keep paring its operating shortfall. A stable cost base paired with rising income is the combination the company needs to close the gap to profitability.

Market reaction and clinical backdrop

Shares changed hands at 16.12 EUR today, off 1.1 percent, though the stock is still up 18 percent since the start of the year. A separate trading session saw the paper close at 16.22 EUR, putting the year-to-date gain at 19 percent.

Investor attention has also been drawn to clinical developments. A study analysis concerning Agamree in DMD stirred activity roughly three weeks ago, and the stock has shed 9.6 percent since then. Against that backdrop, execution on the confirmed annual forecast takes on added weight — delivering the targeted growth volume by year-end would go a long way toward shoring up the company's financial footing.